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Abstract 
People with diabetes are at double the risk of developing depression. Depression 
is associated with increased morbidity and mortality in people with diabetes. 
Levels of A1c have been linked to microvascular complications (e.g., retinopathy, 
nephropathy, and neuropathy) as well as depression. The interrelationship 
between A1c, microvascular complications, and depression has not previously 
been investigated in a comprehensive model, and a better understanding of the 
nature of these associations is needed. Preliminary analyses test the assumption 
that A1c mediates the relationship between group assignment in the Diabetes 
Control and Complications Trial (DCCT) and microvascular complications. The 
primary purpose of the study is to examine multiple mediation models, which 
hypothesize that the severity of microvascular complications mediates the 
relationship between A1c and depressive symptomatology levels. Participants 
were people with type 1 diabetes (N = 1441) enrolled in the DCCT, a longitudinal 
randomized controlled trial investigating intensive insulin treatment and diabetes 
complications, and divided into primary (e.g., no retinopathy) and secondary (e.g., 
mild retinopathy) cohorts. Biological markers were used to measure A1c and 
microvascular complications. Depressive symptomatology was measured by the 
depression subscale of the Symptom Checklist-90-Revised. Simple and multiple 
mediation analyses were used to test proposed models. A1c mediates the 
relationship between DCCT group assignment and microvascular complications. 
vi 
Microvascular complications partially mediate the relationship between A1c and 
depression for the full sample and secondary cohort. Results support the 
hypothesis that the severity of microvascular complications, in part, accounts for 
the association between A1c and depressive symptomatology in people with type 
1 diabetes. 
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Introduction 
Diabetes mellitus is an endocrinological and metabolic disease that involves the 
dysregulation of the use and/or the production of insulin, the hormone that is required for 
regulation of glucose in the body. Hyperglycemia, or elevated blood glucose levels, is the 
hallmark characterization of the disease (The Expert Committee on the & Classification 
of Diabetes Mellitus, 2003). Diabetes is a chronic disorder that affects some 24 million 
people in the United States, or nearly 8% of the population. It is the seventh leading 
causes of death in the country, and the disease doubles the risk of death for its sufferers 
compared to their same-aged non-diabetic counterparts (Centers for Disease Control and 
Prevention, 2008).   
Diabetes Mellitus Classification 
The overwhelming majority of diabetes cases fall into two main, etiologically 
distinct categories: type 1, accounting for about 5 to 10% of all diabetes cases, and type 
2, accounting for about 90 to 95% of diabetes cases (Centers for Disease Control and 
Prevention, 2008). Type 1 diabetes, formerly known as juvenile or insulin-dependent 
diabetes, commonly occurs in childhood and adolescence and is considered an 
autoimmune disease in which beta cells of the pancreas are destroyed by the immune 
system. The destruction of beta cells typically leads to a complete deficiency in insulin 
and treatment with an exogenous supplementation of insulin is essential for survival in 
most cases (The Expert Committee on the & Classification of Diabetes Mellitus, 2003). 
Patients with type 1 diabetes must carefully monitor their blood glucose levels and inject 
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themselves with insulin to regulate glucose levels multiple times throughout each day to 
manage the disease (Executive Summary: Standards of Medical Care in Diabetes, 2009; 
Van Tilburg, et al., 2001).  
Type 2 diabetes, formerly known as non-insulin dependent or adult-onset 
diabetes, is characterized by a resistance to the action of insulin, a relative deficiency of 
insulin production, or both. Insulin resistance leads to deficiency in the necessary insulin 
action required for the proper metabolism of carbohydrates, fats, and proteins (The 
Expert Committee on the & Classification of Diabetes Mellitus, 2003).  Relative insulin 
deficiency means that insulin may still be produced, but the pancreas does not produce a 
sufficient amount of insulin needed to meet the needs of the body (Van Tilburg, et al., 
2001). Autoimmune destruction of pancreatic beta cells does not occur in type 2 diabetes, 
as is central to type 1 diabetes, and lifestyle factors are often associated with the 
development of type 2 diabetes (The Expert Committee on the & Classification of 
Diabetes Mellitus, 2003). Although some patients with type 2 diabetes require insulin 
supplementation to treat their diabetes, treatment with oral medications and lifestyle 
modifications, including changes in diet and exercise, are often sufficient for the 
management of type 2 diabetes (Centers for Disease Control and Prevention, 2008; Van 
Tilburg, et al., 2001). 
Glycemic Control 
Regardless of the type of diabetes, the main goal for treatment is to reach and 
maintain a healthy range of blood glucose levels, often referred to as glycemic control. 
Hemoglobin A1c (A1c) is a weighted measure of the average blood glucose level over 
the past 60 to 90 days, with more weight given to the previous 30 days in the calculation 
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(Lustman, Griffith, Freedland, & Clouse, 1997). A1c shows the degree of glucose 
exposure over time and is often used to measure how well diabetes is being managed 
over several months (Nathan, Kuenen, Borg, Zheng, Schoenfeld, & Heine, 2008). 
Patients with diabetes, especially type 1, routinely test their blood glucose levels, and 
according to Nathan et al. (2008), there is a direct, consistent, and linear relationship 
between mean glucose and A1c. Therefore, A1c is a good measure of how well glucose 
levels are being managed over time on a day-to-day basis. Guidelines for optimum 
management of diabetes suggest that blood glucose levels remain as low as possible 
without risk of hypoglycemia or a  hemoglobin A1c level of 7% or less (Qaseem, et al., 
2007).  Alc is such an informative value for people with diabetes that not only do 
practitioners set treatment goals by this number, it has recently become part of the 
diagnostic criteria for diabetes (Executive Summary: Standards of Medical Care in 
Diabetes, 2010). A1c is a better marker for the presence and severity of diabetes than 
single measure of glucose concentration and current standards state that diabetes should 
be diagnosed when an A1c value at or above 6.5% is present and a repeat of A1c testing 
elicits a similar value to confirm the diagnosis (The International Expert). 
Diabetes Complications 
 Microvascular complications of diabetes, including retinopathy, neuropathy, and 
nephropathy, are caused by damage to and disease of the microvasculature portion, or 
small blood vessels, of the body. Because these diabetes-related complications can 
severely negatively impact quality of life and increase mortality rates, prevention, early 
detection, reduction, and treatment of these complications is of utmost importance for 
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people with diabetes and their healthcare providers. Adequate control of glycemic levels 
is essential for the prevention and control of these often devastating complications.  
Retinopathy. Diabetic retinopathy, a term used to describe damage in the blood 
vessels of the eye, is the most common diabetic eye disease and one of the leading causes 
of blindness in adults in the United States. There are four stages of diabetic retinopathy 
ranging from mild, moderate, and severe nonproliferative retinopathy, to the most severe 
stage of proliferative retinopathy. Microaneyurisms in the blood vessels of the retina, 
blockage of some blood vessels that feed the retina, and advanced blockage of retinal 
blood vessels causing deprivation of blood to the retina are characteristic of mild, 
moderate, and severe nonproliferative retinopathy, respectively. Proliferative retinopathy 
occurs when blockage of retinal blood vessels is so severe the growth of new abnormal 
and fragile blood vessels is triggered which can easily break causing visual damage and 
even blindness (National Eye Institute, 2009). The  majority of people with diabetes will 
experience some degree of retinopathy during the course of the disease, however there is 
variability in stage and severity of the retinopathy and it is in part dependent upon the 
duration of diabetes (Nathan, 1993).  
 Neuropathy. Diabetic neuropathies are nerve disorders caused by diabetes that 
involve damage to nerves throughout the body. Symptoms vary by type of neuropathy 
and by the nerve type affected and some neuropathies may be asymptomatic. Typically, 
symptoms start with tingling, numbness, or pain in the feet and can increase to 
gastrointestinal disturbance, sexual dysfunction, weakness, dizziness, and foot and hand 
muscle atrophy. Different categories of neuropathy exist including peripheral, autonomic, 
proximal, and focal. Peripheral is the most common type of neuropathy in people with 
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diabetes and causes pain or numbness in the extremities (i.e., toes, feet, legs, hands, and 
arms). Autonomic neuropathy affects nerves that control the heart, blood pressure, lungs 
and eyes and can cause bladder, gastrointestinal, and sexual dysfunction and may 
preclude the signs of hypoglycemia from occurring. Proximal neuropathy may lead to 
pain and weakness in the leg and buttocks area, and focal neuropathy is characterized by 
sudden pain or weakness of the muscle and can affect any nerve throughout the body 
(National Diabetes Information Clearinghouse, 2009).  
 Nephropathy. Diabetic nephropathy is damage to or disease of the kidneys that is 
thought to develop as a complication from a combination of elevated blood sugar levels 
and hypertension. Excessive blood sugar may damage and destroy nephrons, the units of 
the kidney that filter waste from the body. Eventually, as more nephrons are destroyed 
albumin protein may leak from the kidney and into the urine. Nephropathy is a 
progressive disease that is the leading cause of long-term kidney failure and end-stage 
kidney disease in the United States and a major cause of illness and even death in people 
with diabetes. Patients with nephropathy often require dialysis or kidney transplantation 
(American Diabetes Association 2004).   
Glycemic Control and Diabetes Complications 
 A1c is considered a value of central concern in the diagnosis and evaluation of 
management in diabetes largely because of a strongly established link between glycemic 
control and long-term diabetes complications. This connection is the basis for the 
recommendation of maintaining an A1c value below 7.0% and regular monitoring of A1c 
levels. A myriad of previous studies have linked poorly controlled A1c levels to 
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numerous microvascular diabetes complications including diabetic peripheral neuropathy, 
retinopathy, and nephropathy, among other types of complications.  
The Diabetes Control and Complications Trial (DCCT). The Diabetes Control 
and Complications Trial (DCCT) was a multicenter randomized longitudinal controlled 
clinical trial designed to investigate the influence of intensive exogenous insulin 
treatment for people with type 1 diabetes on the development and progression of long-
term diabetes complications. The study was designed to examine the effects of standard 
versus intensive insulin treatment on the development, progression, and/or resolution of 
early vascular complications in patients with type 1 diabetes. Two groups of participants 
were enrolled and randomized to either the intensive or standard treatment groups. The 
primary intervention group included participants with no background retinopathy and the 
secondary intervention group included participants with minimal or low levels of 
background retinopathy. Development of microvascular complications was investigated 
in the primary prevention group, whereas the progression and resolution of vascular 
complications was investigated in the secondary prevention group. The goal for the 
experimental group was to maintain blood glucose levels as close to the normal 
nondiabetic range as safely possible, with a target A1c level of less than 6.5%. This was 
achieved with a minimum of three daily insulin injections or use of an insulin pump for 
participants in the intensive treatment group. In contrast, standard care group participants 
had only one to two insulin injections daily (DCCT Research Group, 1993a; DCCT 
Research Group, 1993b). A more detailed description of the study is presented below in 
the procedures section.  
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The DCCT was carried out over more than a 10-year period, with continuous 
enrollment over a 6 year period, and provided definitive evidence demonstrating the role 
of glucose control in the onset, development, and progression of diabetes related 
complications.  Intensive insulin treatment lead to significant reductions in glycemic 
levels for patients with type 1 diabetes and the lowest A1c level for the intensive 
treatment group was reached at 6 months into the study (DCCT Research Group, 1993a). 
A1c levels were significantly lower in the intensive treatment group relative to 
conventional treatment groups after baseline and until the end of the study. Intensive 
insulin treatment lead to significant reductions in glycemic levels for patients with type 1 
diabetes and the lowest A1c level for the intensive treatment group was reached at 6 
months into the study (DCCT Research Group, 1993a). 
Effect of DCCT A1c reduction on retinopathy. Results of the DCCT showed that 
intensive insulin therapy initially led to transient worsening of retinopathy, especially in 
the secondary-intervention cohort during the initiation of therapy. However, these 
abnormalities tended to disappear after about 18 months of treatment. Risk of progression 
of retinopathy was  reduced for patients with early worsening who received intensive 
therapy as compared to those in the standard treatment group (DCCT Research Group, 
1993a; DCCT Research Group, 1995c; DCCT Research Group, 1995d). Cumulative 
retinopathy incidence was not significantly different between the two treatment groups 
until about 3 years of treatment for both the primary and secondary-prevention cohorts. 
At the 5 year point and onward the cumulative incidence of retinopathy was about 50% 
lower for the intensive therapy group than the conventional therapy group in the primary-
prevention cohort.  Intensive therapy reduced the average adjusted risk of retinopathy by 
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76% and risk reduction increased over time in the primary-prevention cohort. In the 
secondary-prevention cohort, intensive therapy reduced the average risk of retinopathy 
progression by 54% over the duration of the study (DCCT Research Group, 1993a; 
DCCT Research Group, 1995c; DCCT Research Group, 1995d).  
Effect of DCCT A1c reduction on nephropathy.  Diabetic nephropathy is initially 
manifested as microalbuminuria, or an increase in urinary albumin excretion. It then 
progresses to overt albuminuria followed by renal failure (Krolewski, Laffel, Krolewski, 
Quinn, & Warram, 1995). In patients with type 1 diabetes, the risk of microalbuminuria is 
strongly related to the degree of hyperglycemia and the risk grows significantly higher 
with A1c levels above 10% (Krolewski et al., 1995). Intensive therapy in the DCCT 
resulted in lower rates of microalbuminiuria and albuminuria in both cohorts as compared 
to the conventional therapy group. The risk of microalbuminuria was reduced by 34% 
and 43% for the primary-prevention and secondary-intervention cohorts in the intensive 
treatment group, respectively. For the combined cohort, the risk of albuminuria and 
microalbuminuria was reduced by 54% and 39% percent, respectively, with the use of 
intensive insulin therapy (DCCT Research Group, 1993a; DCCT Research Group, 
1995b).  
Effect of DCCT A1c reduction on neuropathy. The appearance of clinical 
neuropathy, defined by either abnormal autonomic-nerve testing or abnormal nerve 
conduction in two or more peripheral nerves plus abnormal neurologic examination, was 
reduced by intensive insulin therapy by 69% and 57% for the primary-prevention and 
secondary-intervention cohorts without baseline neuropathy, respectively, as compared to 
their conventional treatment counterparts. Similar reductions in the individual 
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components used to evaluate the presence of clinical neuropathy were also seen with 
intensive therapy (DCCT Research Group, 1993a; DCCT Research Group, 1995a). Even 
after discontinuation of the DCCT, an eight-year follow up of DCCT participants in the 
observational Epidemiology of Diabetes Interventions and Complications (EDIC) showed 
a continued higher rate of incidence of signs, symptoms, and clinically diagnosed 
neuropathy in participants formerly in the conventional treatment group compared to 
those receiving intensive treatment. The higher incidence rates occurred despite the 
narrowing and eventual disappearance of glycemic differences between the two groups 
(Martin et al., 2006).  
UK Prospective Diabetes Study (UKPDS). Similar findings were reported by 
the UK prospective diabetes study (UKPDS). The UKPDS was a clinical trial that 
examined the effect of intensive blood glucose control in over 4000 people with type 2 
diabetes.  The relationship between glycemic exposure and diabetes related complications 
were similar to those in the DCCT and EDIC.  In the prospective study of people with 
type 2 diabetes, each 1% reduction in A1c was associated with a 21% reduction in risk of 
any diabetes related end point, including microvascular complications, macrovascular 
complications, and death. Specifically, a 37% decrease in risk for microvascular 
complications occurred with each 1% decrease in A1c level, providing further support of 
the relationship between glycemic exposure and diabetes related complications (Stratton 
et al., 2000). In summary, research consistently shows a strong predictive association of 
elevated glycemic control levels and greater incidence and severity of diabetes related 
complications (Diabetes Control and Complications Trial Research Group, 1993; Gaster 
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& Hirsch, 1998; Klein, Klein, & Moss, 1996; Klein, Klein, Moss, Davis, & DeMets, 
1988; Stratton, et al., 2000) 
Depression 
 Depression can refer to a transient mood state, a constellation of symptoms, and 
two clinical diagnoses with strict diagnostic criteria (major and minor depression). 
Studies in this area typically examine the extent of depressive symptoms or the presence 
or absence of a clinical diagnosis (major depression or minor depression).  Major and 
minor depression are classified  psychological mood disorders, with major depressive 
disorder affecting approximately 7% of the general population in a given year (Kessler, 
Chiu, Demler, & Walters, 2005). The central characterization of depression is either a 
depressed mood or loss of interest or pleasure over a 2-week period. Other symptoms 
include fluctuations in weight and/or appetite, fluctuations in sleep patterns, psychomotor 
agitation or retardation, fatigue, feelings of worthlessness or excessive guilt, 
concentration difficulties, and suicidal ideation, plans, or attempts.   
Depression and Diabetes 
Depression rates have been estimated to be upwards of twice as high in the 
diabetic population than in the general population. In their 2001 meta-analytic study of 
the prevalence of comorbid depression in adults with diabetes Anderson and colleagues 
analyzed over 40 studies and found the odds of depression in participants with diabetes 
were twice that of their non-diabetic control counterparts (Anderson, Freedland, Clouse, 
& Lustman, 2001). This doubled odds ratio of the prevalence of depression in the diabetic 
population compared to the non-diabetic population was independent of sex, diabetes 
type, subject source, or assessment method. 
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The co-occurrence of depression and diabetes is significant because previous 
research suggests that the comorbidity is associated with  a host of problems including 
poorer medical regimen adherence, increased functional impairment (Ciechanowski, 
Katon, & Russo, 2000), greater symptom burden (Ludman, et al.), higher health care 
costs (Egede, Zheng, & Simpson, 2002), and increased mortality rates (W. Katon, et al., 
2008; W. J. Katon, et al., 2005). One study by Katon and colleagues (2008) found a 36% 
to 38% increased risk for all-cause mortality for diabetic patients with comorbid 
depression compared to their non-depressed diabetic  counterparts. A separate study by 
Katon and colleagues (2005) suggests that both major and minor depression increase 
mortality rates for diabetics with comorbid depression compared to nondepressed 
diabetics by nearly two-fold. 
Glycemic Control and Depression 
As noted earlier, Hemoglobin A1c (A1c), a weighted measure of the average 
blood glucose level over the past 60 to 90 days is typically used to measure how well 
diabetes is being managed over several months (Lustman, Griffith, Freedland, & Clouse, 
1997; Nathan et al., 2008).   The American Diabetes Association recommends a treatment 
goal of A1c <7% (2009), which would be indicative of good glycemic control. Higher 
values of A1c would be indicative of poor glycemic control (American Diabetes 
Association 2009).  
A1c levels have been linked to depression levels in numerous studies. In their 
2000 meta-analytic review of the relationship between depression and glycemic control, 
Lustman and colleagues (Lustman, Anderson, Freedland, de Groot, Carney, & Clouse, 
2000) analyzed 24 cross-sectional studies with a total of 2,817 participants with both type 
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1 and type 2 diabetes. The authors found a significant positive relationship between 
depression and A1c, with a small-to-moderate overall effect size. While this study 
provides further confirmation for the existence of a relationship between depression and 
hyperglycemia, the cross-sectional nature of the data precludes the ability to determine 
either directionality of this relationship, or mechanisms explaining the relationship 
between the two.  
Opposing theories have been proposed regarding the nature of the relationship 
between depression, glycemic control, and related physical complications. These 
competing theories suggest that depression can be either an antecedent to or a 
consequence of symptoms and medical complications related to glycemic control.  The 
antecedent model suggests that depression adversely influences behavioral (e.g., diabetes 
self-care) and physiological mechanisms (e.g., activation of the HPA axis) that result in 
poorer glycemic control and, subsequently, a greater incidence and severity of diabetes 
complications. (William P. Sacco & Bykowski, 2010).  An alternative theory suggests 
that depression is a consequence of poor adherence and/or diabetes medical symptoms 
resulting from poor glycemic control. The consequence model suggest that failure to 
effectively adhere to the complicated diabetes self-management regimen leads to negative 
self-relevant cognitions (e.g., low self-efficacy), poorer glycemic control, and increased 
incidence and severity of medical complications.  Depression results from these 
experiences.  For example, Sacco, Wells, Friedman, Matthew, Perez, and Vaughan 
(2007) found that body mass index (BMI; an indicant of adherence in people with type 2 
diabetes) was associated with diabetes medical symptoms and depression in people with 
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type 2 diabetes.  Diabetes symptoms mediated the relationship between BMI and 
depression, providing support for the consequence model.  
 Similarly, Sacco and Bykowski (2010) found that A1c was associated with 
depression levels in people with type 1 diabetes, and participants’ thoughts about their 
ability to effectively manage their disease (diabetes self-efficacy) mediated this 
relationship. This finding is consistent with the proposal that depression occurring in 
people with type 1 diabetes may be a consequence of negative cognitive appraisals 
resulting from their ability to keep their A1c levels at healthy levels.  
Diabetes Complications and Depressive Symptomatology 
Diabetes complications have been linked to increased levels of depression and 
depressive symptomatolgy within the diabetic population. In their 2001 meta-analytic 
study of the association of depression and diabetes complications de Groot and 
colleagues attempted to evaluate the strength and consistency of this relationship (de 
Groot,  Anderson,  Freedland, Clouse, & Lustman, 2001). Additionally, they sought to 
determine if the relationship between diabetes complications and depressive symptoms 
differed by diabetes type. The authors examined a total of 27 studies that evaluated the 
relationship between depression and at least one complication of diabetes including 
diabetic retinopathy, diabetic neuropathy, diabetic nephropathy or end stage renal 
disease, macrovascular complications, and sexual dysfunction. 
Overall, the authors found a moderate effect size for the relationship between 
depression and all diabetes complications. Moderate effect sizes were found for the 
relationship between depression and all individual diabetes complications (i.e., 
nephropathy, neuropathy, sexual dysfunction, and macrovascular disease alone) apart 
14 
from retinopathy for which a small to moderate effect size was found. Overall, higher 
depression levels were associated with higher numbers and greater severity of diabetes 
related complications. Additional analyses indicated that greater numbers of 
complications were associated with higher depression levels. Further, moderator analyses 
by diabetes type (i.e., type 1 and type 2) indicated similar moderate effect sizes for both 
types. The similar effect size for the relationship between depression and diabetes 
complications in patients with type 1 and type 2 diabetes suggests that common pathways 
may exist to explain this association despite the disparate physiological manifestations 
and distinctions of these diseases. Despite the consistent relationship found between 
depression levels and the presence and severity of diabetes complications, all of the 
studies included in the meta analysis are cross sectional (de Groot et al., 2001).  
Therefore, the temporal relationship between depression and diabetes complications is 
not elucidated through these findings .  
Current Study 
Meta-analytic methods have provided evidence that people with diabetes are at a 
two-fold increased risk of depression relative to their non-diabetic counterparts 
(Anderson et al., 2001). Myriad studies, including large-sample, longitudinal, and 
experimental studies (DCCT Research Group, 1993a) have demonstrated a consistent 
relationship between glycemic control and diabetes-related microvascular complications. 
Poor glycemic control, as measured by elevated A1c levels, is consistently linked to 
greater occurrence and severity of diabetic complications including retinopathy, 
neuropathy, and nephropathy. Meta-analyses also show a consistent relationship between 
glycemic control and depression (Lustman et al., 2000), with poorer glycemic control 
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associated with increased levels of depression and depressive symptomatology. Meta-
analytic techniques also demonstrate a consistent relationship between diabetes related 
complications and depression, with a positive relationship between the number and 
severity of diabetes related complications and levels of depression and depressive 
symptomatology (de Groot et al., 2001).  
Previous research has demonstrated a positive relationship between A1c and 
diabetes complications, A1c and depression, and diabetes complications and depression. 
However, the mechanisms explaining the glycemic control and depression connection 
have not yet been elucidated. Additionally, although the available literature shows 
consistency with the relationships between glycemic control, diabetes complications, and 
depression levels, several limitations exist. Most studies address the relationship between 
two of these variables but do not provide a model examining the relationship between all 
three, leaving the interrelationship between A1c, microvascular diabetes complications, 
and depressive symptomatology unclear. Furthermore, competing theories exist regarding 
the nature of the relationship between diabetes related health complications and 
depression. The antecedent model suggests that depression may contribute to 
physiological and behavioral changes that negatively influence glycemic control and, 
therefore, symptoms and complications. The consequence model suggests that depression 
occurs consequentially to increased medical symptoms and complications that arise from 
poor glycemic control (Sacco et al., 2007; Sacco & Bykowski, 2010).  Further studies 
within these theoretical frameworks are needed to elucidate the nature of the relationship 
between these variables. Furthermore, current literature is largely based on cross-
sectional data precluding the ability to elucidate the temporal relationship between these 
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variables. With the exception of longitudinal experimental studies showing that better 
glycemic control can delay the onset and reduce the severity of diabetes complications 
(DCCT Research Group, 1993a), the cross-sectional nature of much of the research in 
this area does not allow for conclusions about the temporal nature of the relationships to 
be drawn.  
The current study seeks to address the limitations of previous research by 
analyzing the relationship between A1c, microvascular diabetes complications, and 
depressive symptomatology in meditational models using longitudinal experimental data 
based on an a priori theoretical framework. The role of diabetes related complications as 
a mechanism explaining the relationship between A1c and depressive symptomatology 
were explored in the current study within the depression-as-consequence model.  
First, preliminary analyses of the effect of DCCT group assignment (intensive 
treatment versus control) on the presence and severity of microvascular complications 
were evaluated in three separate models (analyzing each microvascular complication 
independently), evaluating A1c as a mediator of the treatment effect. These analyses were 
intended to test the assumption that A1c is the mechanistic variable explaining the 
relationship between DCCT group assignment and lower incidence and severity of 
diabetes related complications and provide evidence for the nature of the relationship 
between DCCT treatment group, A1c, and microvascular complications. These models 
will also help to establish a foundation for further analysis of the relationship between 
A1c, microvascular complications, and depression. The depression-as-consequence 
model was then evaluated in a separate multiple-mediator model with A1c predicting 
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later depressive symptomatology, and microvascular complications examined as 
mediators of the relationship between A1c and depression.   
Four main hypotheses were proposed to test preliminary analyses of the 
relationship between DCCT treatment condition, A1c, and diabetes related microvascular 
complications, as depicted graphically in Figure 1. First, treatment group was expected to 
affect the incidence and severity of diabetes complications, with decreased incidence and 
severity of each complication found in the intensive treatment group.  Second, intensive 
treatment condition was expected to result in lower A1c values. Third, A1c was expected 
to be positively related to the incidence and severity of the microvascular diabetes related 
complications of retinopathy, nephropathy, and neuropathy.  Fourth, it was predicted that 
the effect of treatment condition on the incidence and severity of microvascular 
complications will be fully mediated by A1c. These hypotheses were tested through three 
simple-mediation models for each microvascular diabetes related complication.   
Four main hypotheses were proposed for the relationship between A1c, 
microvascular diabetes related complications, and depressive symptomatology, as 
depicted graphically in Figure 2. First, it was expected that A1c will be positively 
associated with levels of depressive symptomatology. Secondly, A1c was expected to be 
positively related to the presence and severity of diabetes related microvascular 
complications of retinopathy, neuropathy, and nephropathy. Third, microvascular 
diabetes complications were expected to be positively related to depressive 
symptomatology. Lastly, it was predicted that the presence and severity of microvascular 
diabetes related complications will fully mediate the relationship between A1c and 
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depressive symptomatology. These hypotheses were tested in a single multiple-mediator 
analysis.  
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Method 
This study utilized data from the Diabetes Complications and Control Trial 
(DCCT).  The DCCT was a 29 center, randomized clinical trial that compared the effects 
of intensive diabetes therapy to standard treatment on the development and progression of 
complications among individuals with type 1 diabetes. The study was designed to 
examine the effects of standard versus intensive treatment on the development, 
progression, and/or resolution of early vascular complications in patients with type 1 
diabetes. Participants were categorized as either primary or secondary prevention group 
participants based on the absence or presence of minimal diabetic retinopathy, 
respectively, at study initiation (DCCT Research Group, 1986). The study, funded by the 
National Institute of Diabetes and Digestive and Kidney Diseases, was initiated in 1983 
and ended in 1993.   
Participants 
Participants included 1441 generally healthy people with type 1 diabetes who 
ranged from 13 to 39 years of age at the time of randomization. Of the 1441 participants, 
726 who had no diabetic retinopathy were considered primary prevention participants, 
and 715 who had minimal background diabetic retinopathy at the start of the study were 
considered secondary prevention subjects. For the primary prevention group participants, 
eligibility requirements included type 1 diabetes duration for at least one year but no 
more than five years, absence of diabetic retinopathy, visual acuity of at least 50 letters in 
both eyes, and less than 40 mg albumin per 24 hours on a four-hour standardized urine 
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collection. Eligibility criteria for secondary prevention subjects included type 1 diabetes 
duration of at least one year but no more than 15 years, presence of at least one 
microaneurysm in either eye but less retinopathy than would characterize either eye as P2 
or worse based on central grading of stereo fundus photographs, visual acuity of at least 
45 letters in both eyes, and 200 mg or less albumin per 24 hour on a four-hour 
standardized urine collection (DCCT Research Group, 1993b). See Table 1 for full 
demographic information and baseline descriptive values for the full sample, and primary 
prevention and secondary intervention cohorts. 
Exclusion criteria for the study participants were: previous intensive insulin 
treatment; C-peptide levels greater than .2  or .5 pmol/ml for participants with type 1 
diabetes duration greater than 5 years or less than 5 years, respectively; insulin resistance; 
three or more episodes of diabetic ketoacidosis requiring hospitalization in the year 
before randomization; pregnancy or plans for pregnancy within 2 years of randomization; 
hypertension; hyperlipidemia; urinary tract infection;, history of drug or alcohol abuse 
during the five years prior to randomization; diabetic neuropathy, hypothyroidism; 
obesity as defined as a body weight greater than 130% of ideal body weight; chronic 
disease requiring medication for greater than 4 months during the year before 
randomization; history of coronary heart disease or symptomatic peripheral vascular 
disease; history of epilepsy or seizures requiring medication; presence of serious mental 
disorders that would interfere with protocol adherence;  among other criteria (DCCT 
Research Group, 1993b). 
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Materials 
 Depressive symptomatology. The Symptom Checklist 90-Revised (SCL-90-R; 
Derogatis, 1994) was used to measure depressive symptomatology. The SCL-90-R is a 
90-item self-report symptom inventory and is a widely used measure of current 
psychiatric symptoms. It is designed to screen a broad range of psychological problems in 
nine primary symptom dimensions, including: Somatization, Obsessive-Compulsive, 
Interpersonal Sensitivity, Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid 
ideation, and Psychoticism. Additionally, overall psychological distress is measured by 
the Global Severity Index, the Positive Symptom Total, and the Positive Symptom 
Distress Index. Each item is rated on a five-point Likert-type scale of overall distress 
level with scores ranging from 0 (“not at all”) to 4 (“extremely”).  
 The 13 item depression subscale of the SCL-90-R was used to assess the extent to 
which participants experienced depressive symptoms during the past 7 days. A range of 
depressive symptoms were assessed, including dysphoric mood, anhedonia, loss of 
energy, feelings of hopelessness, and thoughts of suicide. Participants rated the severity 
of their depressive symptomatology experiences over the past week on a 5-point scale 
ranging from 0 (“not at all”) to 4 (“extremely”). Total subscale scores are calculated by a 
summation of the item responses, and raw scores can be derived by dividing the total 
score by the number of items on the scale (i.e., 13 for the depression subscale). High 
internal consistency (α = .90) has been reported for the depression subscale of the SCL-
90-R (Derogatis, 1994; Derogatis & Savitz, 1999) .Adequate to good test-retest reliability 
has been established with 1-week (r = .82) and 10-week (r = .75) intervals between 
testing (Derogatis; Derogatis & Savitz). The validity of the depression subscale of the 
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SCL-90-R has been demonstrated through high correlations with other measures of 
depressive symptomatology, including the Beck Depression Inventory (Peveler & 
Fairburn, 1990). The full SCL-90-R depression subscale can be seen in Appendix A. 
 Neuropathy. Clinical and electrodiagnostic criteria were used to determine the 
presence of neuropathy. Neurological evaluations were performed by neurologists 
blinded to treatment group assignment. Any non-diabetic causes of neuropathy were 
identified. Table 2 provides detailed diagnostic criteria and diagnostic categories (DCCT 
Research Group, 1995a).   Further details are provided in Appendix B. 
A 3-point rating scale was used to determine participant neuropathy level. 
Participants were classified as either having definite neuropathy (1), possible neuropathy 
(2), or no neuropathy (3). Definite neuropathy was confirmed by the presence of at least 
two of the following: physical symptoms, abnormalities on the sensory examination, 
and/or absence or decrease in deep-tendon reflexes. Participants with only one abnormal 
finding among physical and sensory symptoms and deep-tendon reflexes, with or without 
abnormal nerve conduction, were classified as having possible clinical neuropathy. All 
other participants were classified as having no neuropathy present (Albers, et al., 2007).  
 Retinopathy. Retinopathy was measured by an assessment of the grading of 
severity of lesions of diabetic retinopathy for each eye every six months. Lesion grades 
were used to determine overall severity of retinopathy according to Early Treatment 
Diabetic Retinopathy Study (ETDRS) interim and final scales. Seven-field stereoscopic 
color fundus photographs were independently graded by two graders masked to treatment 
for rating reliability. Grades that differed by two or more steps were assessed by a senior 
grader who assigned a final grade and a single grading was completed for photographs 
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from nonannual follow-up visits. Additionally, sets of photographs were periodically 
regraded to ensure reproducibility of the grading system. Agreement comparisons were 
complete in 53.3% to 67.6% of cases, within one step 84.3% to 95.0% of cases, and 
within two steps 96.2% to 98.3% of comparison cases (DCCT Research Group, 1995b). 
Retinopathy severity ratings ranged from a scaled score of 10 to a scaled score of 85, 
indicative of the absence of diabetic retinopathy to advanced proliferative diabetic 
retinopathy or partially obscured fundus, respectively. A 10-point scale ranging from 1 to 
10 was used to indicate retinopathy severity based on scaled score ratings. Severity 
ratings included no retinopathy, very mild, mild, moderate, and severe nonproliferative 
diabetic retinopathy, and mild, moderate, high-risk, and advanced proliferative diabetic 
retinopathy (DCCT Research Group, 1995d). Definitions of the ETDRS severity levels of 
retinopathy for can be seen in Table 3.  The ratings of retinopathy levels for each 
individual eye as based on the ETDRS severity level (Table 3) were used to determine 
overall retinopathy severity level for the person (Table 4). Change over time in 
retinopathy severity was a primary outcome of the DCCT. Sustained progression of 
retinopathy was considered present with a cumulative increase by three or more steps on 
the scale at two consecutive visits, shown in Table 4.  
 Nephropathy.  Nephropathy level was measured at annual follow-up visits 
through urine collection over a four-hour collection time period. Urine samples were 
obtained after participants had breakfast and their morning insulin dose and while they 
were resting and in a sitting position. Participants were asked to avoid caffeinated 
beverages the day of and strenuous exercise during the day prior to testing. The level of 
nephropathy was determined by measurement of Albumin Excretion Rate (AER) in units 
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of mg/24 hours and standard Creatinine Clearance in units of ml/min. Participants were 
categorized into a six-point nephropathy level scale based upon AER and Creatinine 
Clearance levels. An AER less than 40mg/24 hours is indicative of level 1 nephropathy, 
and an AER greater than 300 mg/24 hours and a Creatinine Clearance level below 70 
ml/min was indicative of level 6 nephropathy (See Table 5; DCCT Research Group, 
1995b).   
A1c. Glycosylated hemoglobin (A1c) was measured at baseline, at quarterly 
visits, and at study closeout for participants in the standard treatment condition. 
Participants in the intensive treatment group had A1c measured at baseline, monthly 
visits, and study closeout. Blood samples for A1c were assayed in the Central 
Biochemistry Laboratory.  
Procedure 
Participants were randomized to either standard or intensive diabetes therapy and 
followed for an average of 6.5 years (DCCT Research Group, 1993a; DCCT Research 
Group, 1993b). Patients assigned to the standard diabetes management group had one to 
two daily insulin injections with daily self-monitoring. Additionally, patients in the 
standard therapy group received an individualized meal plan with dietitian reinforcement 
every six months, an education program, and standard clinic visits and monitoring at 
three month intervals (DCCT Research Group, 1993b). Patients in the intensive treatment 
group received a minimum of three daily insulin injections or used an insulin pump with 
self-monitoring of blood glucose a minimum of four times daily. They received the same 
dietary management principles as the standard therapy group with reinforcement from the 
dietitian as often as necessary to attain treatment goals. Additionally, patients in the 
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intensive treatment group had weekly clinic visits until stabilization of their diabetes 
treatment program followed by at least monthly clinic visits for medical and 
psychological supervision. Intensive treatment also involved daily telephone contact for 
self-management review and adjustment during the first week of the trial followed by 
monthly telephone calls. Staff was also available at each clinic for patients in the 
intensive treatment group to contact via telephone 24 hours a day. The aim of the 
intensive treatment group was to achieve and maintain normal or as close to normal 
glycemic control, or below 6.5% (DCCT Research Group, 1986).  
Participants attended study clinics quarterly. A1c was measured at quarterly visits, 
retinopathy severity was measured at 6 month intervals, and both nephropathy and 
depressive symptomatology were measured annually. Neuropathy was measured through 
a standardized neurologic history and physical examination by neurologists at baseline, 5 
years, and at the close out of the study.   
Statistical Analysis  
Four models were be tested for this study for the full sample and the primary, as 
well as for secondary intervention cohorts separately. First, three simple-mediation 
models were tested evaluating the meditational role of A1c in the relationship between 
DCCT treatment group assignment (intensive or standard treatment) and the presence and 
severity of microvascular diabetes related complications (see Figure 1). Each diabetes 
complication (i.e., retinopathy, nephropathy, and neuropathy) was tested independently as 
an outcome in the simple-mediation model. The models were tested longitudinally, with 
A1c measurement points preceding each diabetes complication measurement point.  
Level of glycemic control, as measured by A1c, was be averaged over the 4
th
 and 12
th
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quarterly visit (between years 1 and 3 of study participation) of the DCCT to capture the 
early change in glycemic control expected to be achieved by intensive insulin treatment. 
Average levels of microvascular diabetes complications between the 16
th
 and 21
st
 
quarterly visit (between years 4 and 5.25 of study participation) were analyzed in each 
model. This time range captures the greatest variability in the data because diabetes 
complications tend to occur increasingly with disease duration.  DCCT inclusion 
requirements precluded people with advanced retinopathy from participating in the study.  
Therefore, many complications will not occur until later years in the study. Additionally, 
neurologic history and physical examination for neuropathy was measured at baseline, 5 
years, and study end only, so it is important to have a range that captures this data.  
A multiple-mediator model was used to examine the relationship between A1c, 
microvascular diabetes complications, and depressive symptomatology (see Figure 2) to 
provide further evidence of the nature of this relationship over time within the 
depression-as-consequence-model framework. Within the longitudinal model, measures 
of A1c preceded measures of diabetes complications, and measures of complications 
preceded depressive symptomatology measures. Measurement points for A1c and 
microvascular complications for the multiple-mediator model were averaged over the 
same time points as the simple mediator models previously stated. Depressive 
symptomatology, as indicated by total scores on the depression subscale of the SCL-90-R, 
was averaged between the 23
rd
 and 28
th
 quarterly visit (about 6 years into the study) to 
capture the most data for participants who’s depressive symptom levels were not 
measured exactly on the 24
th
 quarterly visit.  
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The models were tested using the mediation bootstrapping Sobel extension 
method as described by Preacher and Hayes (2004 & 2008). Bootstrapping is a 
nonparametric statistical approach that is the most powerful method of obtaining 
confidence limits for specific indirect effects of mediation without assumptions of 
sampling distribution. The multiple resampling bootstrapping methods of the analyses of 
mediator models do not assume normality of the sampling distribution of the indirect 
effect of the independent variable (IV) on the dependent variable (DV) that other 
methods, such as the product-of-coefficients strategy, assume (Preacher & Hayes, 2004, 
2008).  
Simple mediation models were used to test the relationship between group 
assignment (IV), A1c (mediator) and diabetes complications (DV; Preacher & Hayes, 
2004). A multiple-mediator model was used to test the meditational impact of the 
microvascular diabetic complications, retinopathy, neuropathy, and nephropathy 
(mediators) on the relationship between A1c (IV) and depressive symptomatology (DV). 
Testing multiple mediator models provides specific indirect effects of the ability of a 
given mediator to uniquely mediate the effect of the IV on a DV controlling for all other 
mediators in addition to total indirect effects. Relevant variables including gender, age, 
baseline depressive symptomatology, baseline A1c level, baseline diabetes complications 
severity (i.e., level of retinopathy, baseline albumin excretion, and neuropathy ratings), 
duration of diabetes, and smoking status were controlled for in each of the four mediation 
models tested. Baseline retinopathy levels were not controlled for the primary 
intervention cohort because inclusion requirements precluded the presence of retinopathy 
in this group. 
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The simple mediation models answers the four hypotheses regarding the 
relationship between DCCT group assignment, A1c, and diabetes related complications 
for each diabetes related microvascular complication by providing the direct effects of 
group assignment on the incidence and severity of each complication (hypothesis 1), 
direct effects of group assignment on A1c (hypothesis 2), direct effects of A1c on the 
incidence and severity of microvascular complications (hypothesis 3), and the indirect 
effects of group assignment on the incidence and severity of each microvascular 
complication with A1 as a mediator of that relationship (hypothesis 4). The multiple 
mediator model answers all four hypotheses regarding the relationship between A1c, 
microvascular complications, and depressive symptomatology by providing direct effects 
of A1c on depressive symptomatology (hypothesis 1), direct effects of A1c on diabetes 
complications (hypothesis 2), direct effects of diabetes complications on depressive 
symptomatology (hypothesis 3), and specific and total indirect effects of A1c on 
depressive symptomatology with diabetes complications as mediators of that relationship 
(hypothesis 4).  
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Table 1 
Participant Baseline Descriptive Characteristics and Demographic Information   
 
Full  
Sample 
 Primary 
Cohort 
 Secondary 
Cohort 
Characteristic (N = 1441)  (n = 726)  (n = 715) 
 M (SD)  M (SD)  M (SD) 
Age
a
  27.09 (7.11)  26.67 (7.41)  27.51 (6.78) 
Education
a
  14.09 (2.28)  13.92 (2.43)  14.26 (2.11) 
Diabetes duration
b
  69.78 (49.67)  33.46 (16.39)  106.65 (44.72) 
A1c 8.89 (1.59)  8.82 (1.67)  8.97 (1.50) 
Retinopathy 2.18 (1.57  1 (0.00)  3.38 (1.44) 
Albumin Excretion Rate 15.93 (18.76)  11.82 (8.29)  20.10 (24.60) 
Neuropathy  2.59 (.65)  2.70 (.56)  2.48 (.72) 
Depression 5.32 (5.05)  5.54 (5.27)  5.10 (4.81) 
 N (%)  N (%)  N (%) 
Male gender 761 (52.8)  378 (52.1)  383 (53.6) 
Married  706 (49.0)  351 (48.3)  355 (49.7) 
White race 1391 (96.5)  698 (96.1)  693 (96.9) 
Current smoker 304 (21.1)  145 (20.0)  159 (22.2) 
Intensive treatment group  711 (49.3)  348 (47.9)  363 (50.8) 
Note.
a 
= in years. 
b
 = in months.  
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Table 2 
Diabetes Control and Complications Trial Neurologic End Point Definitions 
 
Category Definition 
 
Confirmed clinical 
neuropathy 
 
A finding of definite clinical neuropathy by physical 
examination and history confirmed by unequivocal 
abnormality of either nerve conduction or autonomic 
nervous system response as defined below 
 
Clinical neuropathy A definite diagnosis of peripheral diabetic neuropathy by 
clinical examination based on the presence of at least two 
of the following: 
Physical symptoms 
Abnormalities on sensory examination 
Absent or decreased deep-tendon reflexes 
 
Abnormal nerve 
conduction 
At least one abnormal conduction attribute on each of at 
least two anatomically distinct peripheral nerves according 
to the following standards: 
Median motor nerve: Amplitude < 4.2 mV; Conduction 
velocity < 49.0 m/sec; F-wave latency > 31.8 m/sec 
Median sensory nerve: Amplitude < 10.0 µV; Conduction 
velocity < 48.0 m/sec;  
Peroneal nerve: Amplitude < 2.5 mV; Conduction velocity 
< 40.0 m/sec; F-wave latency > 56.0 m/sec 
 Sural nerve: Amplitude <5.0 µV; Conduction velocity < 
40.0 m/sec 
 
Abnormal autonomic 
response 
Any of the following indications of cardiac autonomic 
neuropathy: 
R-R variation (mean resultant) < 15.0 
R-R variation < 20.0 in combination with Valsalva ratio < 
1.5 
Orthostatic hypotension caused by autonomic neuropathy 
as indicated by a decrease of at least 10 mm Hg in 
diastolic blood pressure in postural studies confirmed by 
blunted norepinephrine response in plasma catecholamine 
specimens 
 
Subclinical neuropathy Abnormal nerve conduction, autonomic nervous system 
response, or both without a definite diagnosis of peripheral 
neuropathy by clinical examination  
Note. From: DCCT Research Group (1995a). The effect of intensive diabetes therapy on 
the development and progression of neuropathy. Annals of Internal Medicine, 122, 561-
568. 
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Table 3 
Abbreviated Summary of the Final Version of the Early Treatment Diabetic Retinopathy 
Study Scale of Diabetic Retinopathy Severity for Individual Eyes  
Scale Level Severity Definition 
1 10 No retinopathy Diabetic retinopathy absent 
 
2 20 Very mild NPDR Microaneurysms only 
 
3 35 Mild NPDR Microaneurysms plus hard exudates, cotton-wool 
spots, and/or mild retinal hemorrhages 
 
4 43 Moderate NPDR Microaneurysms plus mild IRMA or moderate 
retinal hemorrhages 
 
5 47 Moderate NPDR More extensive IRMA, severe retinal 
hemorrhages, or venous beading in one quadrant 
only 
 
6 53 Severe NPDR Severe retinal hemorrhages in four quadrants, or 
venous beading in at least two quadrants, or 
moderately severe IRMA in at least one quadrant 
 
7 61 Mild PDR NVE <0.5 disc area in one or more quadrants 
 
8 65 Moderate PDR NVE ≥0.5 disc area in one or more quadrants or 
NVD <0.25-0.33 disc area 
 
9 71-75 High-risk PDR NVD≥0.25-0.33 disc area and/or vitreous 
hemorrhage 
 
10 81-85 Advanced PDR  Fundus partially obscured 
Note. NPDR = nonproliferative diabetic retinopathy; IRMA = intraretinal microvascular 
abnormalities; PDR = proliferative diabetic retinopathy; NVE = new vessels elsewhere; 
NVD = new vessels on or within 1 disc diameter of optic disc.  
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Table 4 
Abbreviated Final Version of the Early Treatment Diabetic Retinopathy Study Scale of 
Diabetic Retinopathy Severity for Persons 
Step Level (Worse Eye/Better Eye) 
1 10/10 
2 20/<20 
3 20/20 
4 35/<35 
5 35/35 
6 43/<43 
7 43/43 
8 47/<47 
9 47/47 
10 53/<53 
11 53/53 
12-23 ≥61/<61 
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Table 5 
Diabetes Control and Complications Trial Scale of Nephropathy 
Level Description 
1 AER < 40mg/24hrs 
1a AER < 15 mg/24hrs 
1b 15 ≤ AER < 40 mg/24rs 
2 40 ≤ AER < 100 mg/24hrs 
3 100 ≤ AER < 200 mg/24hrs 
4 200 ≤ AER < 300 mg/24hrs 
5 AER ≥ 300 mg/24hrs and Creatinine Clearance ≥ 70 ml/min/1.73m2 
6 AER ≥ 300 mg/24hrs and Creatinine Clearance < 70 ml/min/1.73m2 
Note. AER = Albumin excretion rate. 
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Figure 1. Graphical representation of the hypothesized simple-mediator model of DCCT 
intervention treatment condition, A1c, and microvascular diabetes complications. Three 
individual models with each microvascular complication as the dependent variable will 
be tested.   
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Figure 2. Graphical representation of the hypothesized multiple-mediator model of A1c, 
microvascular diabetes complications, and depressive symptomatology.  
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Results 
Descriptives, t-tests, and Correlational Analyses 
 Mean values and standard deviations for average A1c between quarterly visits 4 
through 12, average retinopathy, nephropathy, and neuropathy levels between quarterly 
visits 16 through 21, and average depressive symptomatology levels between quarterly 
visit 23 and 28 are presented in Table 6. Values are presented for the full DCCT sample 
and the primary and secondary intervention cohorts separately. Group comparisons 
showed that participants in the primary intervention group had lower levels of 
retinopathy, nephropathy, and neuropathy than participants in the secondary intervention 
cohort (t(952.61) = -21.98, p < .001, d = .51, t(891.05) = -7.02, p < .001, d = .37, 
t(1220.56) = 4.57, p < .001, d = .27, respectively), as expected. Average A1c levels were 
higher in the primary intervention cohort than the secondary intervention cohort 
(t(1432.52) = 2.07, p < .05, d = .11) and there was no difference in average depression 
levels between the primary and secondary intervention cohorts (t(807) = 1.65, n.s., d = 
.12).  
Additionally, Pearson product-moment correlations between A1c, microvascular 
complications, and depressive symptomatolgoy and point-biserial correlations between 
these variables and DCCT treatment group assignment (standard vs. intensive treatment) 
are presented in table 6 for the full sample, primary intervention cohort, and secondary 
intervention cohort. As expected, A1c was significantly related to DCCT treatment group 
assignment and all microvascular complications in the expected direction in the full 
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sample as well as in both the primary and secondary intervention cohorts. Additionally, 
the microvascular complications were all significantly correlated in all samples. A1c was 
significantly related to depression in the full sample and the secondary intervention 
cohort, but not in the primary intervention cohort. DCCT treatment group assignment was 
significantly related to all variables except depression in the full sample and primary 
intervention group. Treatment group assignment and depression were significantly related 
in the secondary intervention group, however. Depressive symptomatology level was 
significantly related to neuropathy in the full sample and retinopathy and neuropathy in 
the secondary intervention cohort, but was not significantly correlated to any 
microvascular complications in the primary intervention cohort.  
Single Mediation Models Analyses 
 Three proposed simple mediation models, illustrated in Figure 1, included A1c as 
a mediating variable in the relationship between DCCT treatment group assignment and 
retinopathy, nephropathy, and neuropathy. These three mediation models were tested for 
the full DCCT sample as well as for the primary and secondary intervention cohorts 
separately, resulting in a total of nine models. Age, gender, duration of diabetes, smoking 
status, and baseline values of A1c, depressive symptomatology, and microvascular 
complications were entered as covariates to control for their possible effects in each 
model. Retinopathy was omitted as a covariate for the primary intervention cohort model. 
It was predicted that DCCT treatment group assignment would be related to the presence 
and severity of each microvascular complication and that A1c would mediate these 
relationships.  
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To test for the significance of the mediation effect the Preacher and Hayes (2008) 
method of calculating standard errors and confidence intervals was used with 5,000 
bootstrap samples used to estimate the bias corrected and accelerated confidence 
intervals. Results of these analyses can are summarized in Table 7. The total effect of 
DCCT intervention group on the severity of microvascular complications was significant 
for all three complications in the full sample as well as in the primary and secondary 
intervention cohorts. Indirect effects were significant for all of the models tested except 
for the model testing the meditational role of A1c on the relationship between DCCT 
treatment group and nephropathy in the primary intervention cohort. With inclusion of 
A1c as a mediating variable, the direct effect of DCCT group assignment on 
microvascular complications was nonsignificant for all models tested. This suggests that, 
with one exception of nephropathy in the primary intervention cohort, there is a 
significant mediation effect of DCCT treatment group assignment on microvascular 
complications through A1c, and A1c fully mediates the relationship between DCCT 
group assignment and microvascular complications.  The full models, including DCCT 
treatment group assignment, A1c, and all covariates, accounted for a significant 
proportion of the variance (p < .001) in microvascular complication levels for all models 
tested. These results provide evidence for the assumption that the differences in the 
severity of microvascular complications seen in the DCCT are in fact due to differences 
in A1c resulting from the differences in treatment.   
Multiple Mediation Models Analyses 
A proposed multiple mediation model, illustrated in Figure 2, included 
retinopathy, nephropathy, and neuropathy as mediating variables in the relationship 
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between A1c and level of depressive symptomatology. The multiple mediator model was 
tested for the full DCCT sample as well as for the primary and secondary intervention 
cohorts separately, resulting in a total of three multiple mediator models. Age, gender, 
duration of diabetes, smoking status, and baseline values of A1c, depressive 
symptomatology, and microvascular complications were entered as covariates to control 
for their possible effects in each model. Because participants in the primary intervention 
cohort had no baseline retinopathy, retinopathy was omitted as a covariate for the primary 
intervention cohort model. It was predicted that A1c would be positively related to 
depressive symptomatology and that the severity of microvascular complications would 
mediate this relationship. Multiple mediator models in which all of the microvascular 
complications were entered simultaneously allowed for investigation of the total indirect 
effect of microvascular complications on the relationship between A1c and depressive 
symptomatology as well as the specific indirect effects of each of the individual 
complications while controlling for the other complications. 
Results of the tests of multiple mediators for the full DCCT sample, the primary 
intervention cohort, and the secondary intervention cohort can be found in Figure 3, 
Figure 4, and Figure 5, respectively. In both the full DCCT sample and the secondary 
intervention cohort, total effects (c) indicated significant and substantial relations 
between A1c and depressive symptomatology levels. However, the total effect of the 
relationship between A1c and depressive symptomatology was not significant in the 
primary prevention cohort.  
To test for the significance of the mediation effect the Preacher and Hayes (2008) 
method was used with 5,000 bootstrap samples used to estimate the bias corrected and 
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accelerated confidence intervals. Significance tests of the mediation effects can be found 
in Table 8. Total indirect effects were significant for the full DCCT sample as well as for 
the secondary intervention cohort. For the full DCCT sample, both nephropathy and 
neuropathy had significant (p < .05) specific indirect effects on the relationship between 
A1c and depressive symptomatology. None of the specific indirect effects, however, were 
significant for the primary intervention or secondary intervention cohorts. Contrasts of 
specific indirect effects were examined and all pairwise contrasts of indirect effects were 
nonsignificant, indicating that the magnitude of the specific indirect effects of the 
different microvascular complications could not be distinguished from one another in any 
of the models tested.  
 Despite significant mediation, the direct effects (c’) remained significant in both 
the full DCCT sample and the secondary intervention cohort, although the strength of the 
relationship was attenuated, suggesting that the presence and severity of microvascular 
complications partially mediates the relationship between A1c and depressive 
symptomatology in these samples. Total effects, mediation effects, and direct effects 
were all nonsignificant in the primary intervention cohort. The full models, including 
A1c, the three microvascular complications, and all covariates, accounted for a 
significant proportion of the variance (p < .001) in depressive symptomatology levels for 
all models tested. The models explained 18, 14, and 22 percent of the variance in 
depressive symptomatology levels for the full sample, primary intervention cohort, and 
secondary intervention cohort, respectively.  
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Table 6 
Descriptive Statistics and Correlations of Average A1c, Retinopathy, Nephropathy, 
Neuropathy, and Depressive Symptomatology Levels.  
Sample  1 2 3 4 5 M SD N 
Full
a 
1. A1c average ––     8.17 1.57 1440 
 2. Retinopathy   .24** ––    3.25 2.39 1359 
 3. Nephropathy   .18** .35** ––   1.17  .61 1419 
 4. Neuropathy -.16** -.21** -.15** ––  2.42  .76 1240 
 5. Depression  .11**   .03   .06 -.12** –– 5.17 6.10   809 
 6. DCCT Group -.62** -.16** -.09**  .13** -.06 –– –– 1441 
          
Primary
b 
1. A1c average ––     8.25 1.63   726 
 2. Retinopathy  .45** ––    2.01 1.11   657 
 3. Nephropathy  .16** .18** ––   1.06  .30   716 
 4. Neuropathy -.17** -.13** -.09* ––  2.53  .71   554 
 5. Depression  -.02  -.05 .03   -.11 –– 5.62 6.22   310 
 6. DCCT Group -.65** -.24** -.09*   .15** .03 –– ––   726 
          
Secondary
c 
1. A1c average ––     8.08 1.50   714 
 2. Retinopathy  .31** ––    4.41 2.66   702 
 3. Nephropathy  .23** .32** ––   1.28  .79   703 
 4. Neuropathy  -.18** -.20** -.16** ––  2.33  .79   686 
 5. Depression .19**  .10*   .08 -.15** –– 4.89 6.02   499 
 6. DCCT Group -.58** -.20** -.11** .13** -.11* –– ––   715 
Note. * p < .01. ** p < .001.  Average A1c values calculated between quarterly visits 
(QV) 4-12.  
Average retinopathy, nephropathy, and neuropathy values calculated between QV 16-21. 
Average depressive symptomatology levels between QV 23-28.  
a
 = ns for correlations range from 777 – 1419. b = ns for correlations range from 297 – 
716. 
c
 = ns for correlations range from 480 – 704.  
  
42 
T
ab
le
 7
 
M
ed
ia
ti
o
n
 o
f 
th
e 
E
ff
ec
t 
o
f 
D
C
C
T
 T
re
a
tm
en
t 
G
ro
u
p
 o
n
 M
ic
ro
va
sc
u
la
r 
C
o
m
p
li
ca
ti
o
n
s 
th
ro
u
g
h
 A
1
c 
fo
r 
th
e 
fu
ll
 D
C
C
T
 G
ro
u
p
, 
a
n
d
 t
h
e 
P
ri
m
a
ry
 a
n
d
 S
ec
o
n
d
a
ry
 I
n
te
rv
en
ti
o
n
 C
o
h
o
rt
s.
  
  
D
ep
en
d
en
t 
V
ar
ia
b
le
 (
D
V
) 
E
ff
ec
t 
o
f 
IV
 
o
n
 M
 (
a
) 
E
ff
ec
t 
o
f 
M
 
o
n
 D
V
 (
b
) 
T
o
ta
l 
E
ff
ec
t 
(c
) 
In
d
ir
ec
t 
E
ff
ec
t 
D
ir
ec
t 
E
ff
ec
t 
(c
’)
 
R
2
 
(a
b
) 
(S
E
) 
9
5
%
 C
I 
F
u
ll
  
R
et
in
o
p
at
h
y
a
  
-1
.9
3
*
*
*
 
.3
3
*
*
*
 
-.
7
3
*
*
*
 
-.
6
3
*
 (
.1
0
) 
[-
.8
3
, 
-.
4
4
] 
-.
1
0
 
.5
8
*
*
*
 
 
N
ep
h
ro
p
at
h
y
b
 
-1
.9
5
*
*
*
 
.0
5
*
*
*
 
-.
1
1
*
*
*
 
-.
1
1
*
 (
.0
3
) 
[-
.1
8
, 
-.
0
5
] 
-.
0
0
0
4
 
.2
1
*
*
*
 
 
N
eu
ro
p
at
h
y
c
 
-1
.9
2
*
*
*
 
-.
0
9
*
*
*
 
.2
1
*
*
*
 
.1
6
*
 (
.0
4
) 
[.
0
9
, 
.2
4
] 
.0
5
 
.2
0
*
*
*
 
 
 
 
 
 
 
 
 
 
P
ri
m
ar
y
 
R
et
in
o
p
at
h
y
d
 
-2
.0
7
*
*
*
 
.2
0
*
*
*
 
-.
5
2
*
*
*
 
-.
4
2
*
 (
.1
0
) 
[-
.6
2
, 
-.
2
5
] 
-.
1
0
 
.3
3
*
*
*
 
 
N
ep
h
ro
p
at
h
y
e
 
-2
.1
1
*
*
*
 
.0
1
 
-.
0
6
*
*
 
-.
0
3
 (
.0
2
) 
[-
.0
7
, 
.0
0
3
] 
-.
0
3
 
.0
9
*
*
*
 
 
N
eu
ro
p
at
h
y
f 
-2
.0
7
*
*
*
 
-.
0
7
*
 
.2
1
*
*
*
 
.1
5
*
 (
.0
6
) 
[.
0
3
, 
.2
7
] 
.0
6
 
.1
5
*
*
*
 
 
 
 
 
 
 
 
 
 
S
ec
o
n
d
ar
y
 
R
et
in
o
p
at
h
y
g
 
-1
.7
8
*
*
*
 
.4
5
*
*
*
 
-.
9
2
*
*
*
 
-.
8
0
*
 (
.1
6
) 
[-
1
.1
4
, 
-.
5
0
] 
-.
1
2
 
.4
9
*
*
*
 
 
N
ep
h
ro
p
at
h
y
h
 
-1
.7
9
*
*
*
 
.1
0
*
*
*
 
-.
1
7
*
*
 
-.
1
8
*
 (
.0
6
) 
[-
.3
2
, 
-.
0
8
] 
.0
1
 
.2
4
*
*
*
 
 
N
eu
ro
p
at
h
y
i 
-1
.7
9
*
*
*
 
-.
1
0
*
*
*
 
.2
1
*
*
*
 
.1
8
*
 (
.0
5
) 
[.
0
8
, 
.2
8
] 
.0
3
 
.2
2
*
*
*
 
N
o
te
. 
*
 p
 <
 .
0
5
. 
*
*
 p
 <
 .
0
1
. 
*
*
*
 p
 <
 .
0
0
1
. 
A
ll
 c
o
ef
fi
ci
en
ts
 r
ep
re
se
n
t 
p
o
in
t 
es
ti
m
at
es
 w
h
il
e 
co
n
tr
o
ll
in
g
 f
o
r 
g
en
d
er
, 
ag
e,
 d
ia
b
et
es
 d
u
ra
ti
o
n
, 
sm
o
k
in
g
 s
ta
tu
s,
 a
n
d
 b
as
el
in
e 
v
al
u
es
 o
f 
A
1
c,
 
d
ep
re
ss
iv
e 
sy
m
p
to
m
at
o
lo
g
y
, 
an
d
 m
ic
ro
v
as
cu
la
r 
co
m
p
li
ca
ti
o
n
s.
  
a
 n
 =
 1
3
4
7
. 
b
 n
 =
 1
4
0
7
. 
c  
n
 =
 1
2
3
2
. 
d
 n
 =
 6
5
2
. 
e  
n
 =
 7
1
1
. 
f  n
 =
 5
5
2
. 
g
 n
 =
 6
9
5
. 
h
 n
 =
 6
9
6
. 
i  n
 =
 6
8
0
. 
 
43 
T
ab
le
 8
 
M
ed
ia
ti
o
n
 o
f 
th
e 
ef
fe
ct
 o
f 
A
1
c 
o
n
 d
ep
re
ss
iv
e 
sy
m
p
to
m
at
o
lo
g
y
 t
h
ro
u
g
h
 t
h
e 
m
ic
ro
v
as
cu
la
r 
co
m
p
li
ca
ti
o
n
s 
o
f 
re
ti
n
o
p
at
h
y
, 
n
ep
h
ro
p
at
h
y
, 
an
d
 n
eu
ro
p
at
h
y
 i
n
 t
h
e 
fu
ll
 D
C
C
T
 p
ar
ti
ci
p
an
t 
co
h
o
rt
, 
p
ri
m
ar
y
 p
re
v
en
ti
o
n
 c
o
h
o
rt
, 
an
d
 s
ec
o
n
d
ar
y
 i
n
te
rv
en
ti
o
n
 c
o
h
o
rt
. 
M
ed
ia
to
rs
  
F
u
ll
 D
C
C
T
 C
o
h
o
rt
a 
P
ri
m
ar
y
 P
re
v
en
ti
o
n
 C
o
h
o
rt
b
 
S
ec
o
n
d
ar
y
 I
n
te
rv
en
ti
o
n
 C
o
h
o
rt
c 
 
In
d
ir
ec
t 
E
ff
ec
ts
 
B
o
o
ts
tr
ap
p
in
g
  
In
d
ir
ec
t 
E
ff
ec
ts
 
B
o
o
ts
tr
ap
p
in
g
  
In
d
ir
ec
t 
E
ff
ec
ts
 
B
o
o
ts
tr
ap
p
in
g
  
 
C
o
ef
fi
ci
en
t 
(S
E
) 
9
5
%
 C
I 
C
o
ef
fi
ci
en
t 
(S
E
) 
9
5
%
 C
I 
C
o
ef
fi
ci
en
t 
(S
E
) 
9
5
%
 C
I 
T
o
ta
l 
m
ed
ia
te
d
 e
ff
ec
t 
.1
9
*
 (
.0
7
) 
  
 [
.0
6
, 
.3
4
] 
.0
3
 (
.1
0
) 
[-
.1
5
, 
.2
7
] 
.2
2
*
 (
.0
9
) 
[.
0
6
, 
.4
3
] 
R
et
in
o
p
at
h
y
 
.0
6
  
 (
.0
5
) 
  
 [
-.
0
2
, 
.1
7
] 
-.
0
6
 (
.0
7
) 
[-
.2
3
, 
.0
5
] 
.1
1
  
(.
0
7
) 
[-
.0
1
, 
.2
7
] 
N
ep
h
ro
p
at
h
y
 
.0
5
*
 (
.0
3
) 
[.
0
0
0
1
, 
.1
2
] 
.0
1
 (
.0
3
) 
[-
.0
3
,.
1
3
] 
.0
5
  
(.
0
5
) 
[-
.0
2
, 
.1
6
] 
N
eu
ro
p
at
h
y
 
.0
8
*
 (
.0
4
) 
  
  
[.
0
1
, 
.1
8
] 
.0
8
 (
.0
7
) 
[-
.0
2
, 
.2
7
] 
.0
6
  
(.
0
5
) 
[-
.0
2
, 
.1
8
] 
N
o
te
. 
*
p
 <
 .
0
5
 a
s 
d
et
er
m
in
ed
 b
y
 t
h
e 
9
5
%
 b
ia
s 
co
rr
ec
te
d
 a
n
d
 a
cc
el
er
at
ed
 b
o
o
ts
tr
ap
p
in
g
 
co
n
fi
d
en
ce
 i
n
te
rv
al
 (
C
I)
. 
A
ll
 c
o
ef
fi
ci
en
ts
 r
ep
re
se
n
t 
p
o
in
t 
es
ti
m
at
es
 w
h
il
e 
co
n
tr
o
ll
in
g
 f
o
r 
g
en
d
er
, 
ag
e,
 d
ia
b
et
es
 d
u
ra
ti
o
n
, 
sm
o
k
in
g
 s
ta
tu
s,
 a
n
d
 b
as
el
in
e 
v
al
u
es
 o
f 
A
1
c,
 d
ep
re
ss
iv
e 
sy
m
p
to
m
at
o
lo
g
y
, 
an
d
 m
ic
ro
v
as
cu
la
r 
co
m
p
li
ca
ti
o
n
s.
  
a n
 =
 7
6
6
, 
b
n
 =
 2
9
5
, 
c n
 =
 4
7
1
. 
  
44 
B = .52*** (.14) 
B = .33* (.15) 
Direct Effects 
 
 
 
 
 
 
 
Indirect Effects 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Multiple mediation test of the role of microvascular complications in the 
relationship between A1c and depressive symptomatology for the full DCCT sample. All 
coefficients represent unstandardized regression coefficients (Standard Error) while 
controlling for age, gender, diabetes duration, smoking status, and baseline levels of A1c, 
depression, and microvascular complications. 
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Figure 4. Multiple mediation test of the role of microvascular complications in the 
relationship between A1c and depressive symptomatology for the primary prevention 
cohort of the DCCT. All coefficients represent unstandardized regression coefficients 
(standard error) while controlling for age, gender, diabetes duration, smoking status, and 
baseline levels of A1c, depression, and microvascular complications. 
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Figure 5.  Multiple mediation test of the role of microvascular complications in the 
relationship between A1c and depressive symptomatology for the secondary intervention 
cohort of the  DCCT. All coefficients represent unstandardized regression coefficients 
(standard error) while controlling for age, gender, diabetes duration, smoking status, and 
baseline levels of A1c, depression, and microvascular complications. 
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Discussion  
The Relationship Between A1c, Complications, and Depressive Symptoms 
 The current study examined the relationship between A1c, microvascular 
complications, and depressive symptomatology in people with type 1 diabetes. The 
DCCT data set was used to examine these relationships because it provides longitudinal 
data which enhances our understanding of the temporal sequence involved in these 
relationships. Results from preliminary analyses were consistent with hypotheses, as A1c 
fully explained the relationship between DCCT treatment group and the severity of three 
microvascular complications: retinopathy, neuropathy, and nephropathy. The primary 
goal of the study was to determine if the severity of these microvascular complications 
explained the relationship between A1c and depressive symptoms. Consistent with 
hypotheses, the severity of microvascular complications helps to explain the relationship 
between A1c and depressive symptoms. The severity of microvascular complications 
partially mediated the relationship between A1c and depressive symptoms for the full 
sample as well as for a secondary intervention subset of participants who began the study 
with early stage levels of retinopathy. However, in the primary prevention cohort whose 
members had no baseline retinopathy, A1c was not predictive of depressive 
symptomatology levels, and microvascular complications did not mediate the relationship 
between A1c and depressive symptoms. For the full sample, the A1c-depressive 
symptoms relationship was explained in part by the combined effect of all three 
microvascular complications.  However, further analyses indicated that the combined 
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effect was primarily due to specific indirect effects of nephropathy and neuropathy (but 
not retinopathy). Additionally, in the secondary intervention cohort, the A1c-depressive 
symptoms relationship was explained in part by the combined effect of all three 
microvascular complications, but not by specific effects of the individual microvascular 
complications. These results provide support for diabetic complications as one 
explanation of the relationship between A1c and depressive symptoms, specifically in 
later stages of the diabetes disease process when microvascular complications become 
more severe.  
 The results of the present study suggest that microvascular complications of 
diabetes significantly contribute to depressive symptom levels and explain the 
relationship between A1c, both a measure of glycemic levels over time as well as an 
index of success in the self-management of diabetes, and depression levels. These 
findings are consistent with a consequence model of diabetes and depression, which 
suggests that depressive symptoms result as a consequence of medical problems that 
occur as a result of poor glycemic control (W. P. Sacco, et al., 2007; W. P. Sacco, et al., 
2005). The antecedent theory of depression in diabetes, which suggests that medical 
problems arise as a result of depression leading to decreased self-management and 
increased A1c, may be a reasonable alternative or even a complement to the consequent 
model; i.e., a bidirectional model is plausible.  However, the longitudinal nature of the 
current models tested provides evidence for the hypothesized temporal relationship 
between A1c, diabetes related complications, and depressive symptom levels. This 
temporal evidence lends further support for the consequence model of the development of 
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depression in people with diabetes and its relation to A1c and associated medical 
problems.  
 Additionally, the results suggest that the explanatory role of microvascular 
complications in the relationship between A1c and depression tends to be most evident 
for people with more severe diabetic complications. Results for the full sample were 
driven by the secondary cohort, which was comprised of people with significantly higher 
baseline levels of retinopathy, longer diabetes disease duration, and, therefore, longer 
exposure to hyperglycemia than their primary cohort counterparts. The difference in the 
role of microvascular complications in the relationship between A1c and depressive 
symptoms for the cohorts may be reflective of these differences. Microvascular 
complications tend to develop and progress with longer disease duration (Fong, et al., 
2004; Luk, et al., 2008; Moss, Klein, & Klein, 1992; Orchard, et al., 1990), and are often 
asymptomatic at early stages (Boulton, et al., 2005; Fong, et al., 2004; Soldo, Brkljacic, 
Bozikov, Drinkovic, & Hauser, 1997). Based on these trends, the detrimental effects of 
microvascular complications on psychological health are perhaps not evident until the 
complications are sufficiently severe enough to be symptomatic. The symptoms of these 
diabetes complications may be disruptive through pain and functional impairment (W. P. 
Sacco, Bykowski, & Mayhew, 2010) that result with increasing severity of the 
complications, consequentially resulting in higher depressive symptom levels.  
Strengths  
These results are consistent with previous studies which have shown positive 
associations between A1c, depression, and microvascular complications (de Groot, 
Anderson, Freedland, Clouse, & Lustman, 2001; Lustman, et al., 2000). Similarly, results 
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are consistent with the few previous longitudinal studies of A1c and depressive 
symptoms available. Longitudinal analysis of  A1c and depressive symptoms in people 
with type 2 diabetes suggest that poor glycemic control can increase risk of depressive 
symptoms for people with intensive (i.e., insulin) treatment regimen, but not those on oral 
medication alone (Aikens, Perkins, Lipton, & Piette, 2009). An additional longitudinal 
investigation shows a positive relationship between A1c and depression over time, but 
the nature of the data precludes causal inferences (Richardson, Egede, Mueller, Echols, & 
Gebregziabher, 2008).  However, most studies use cross-sectional data which severely 
limits the conclusions that can be drawn from the results. Furthermore, no previous 
studies have examined the interrelationship among these variables in a single model using 
longitudinal experimental data, as the current study does, which provides evidence of a 
temporal relationship between the variables. The present study also adds to the existing 
body of research by providing a comprehensive theoretically based model of the 
relationship between these variables over time providing evidence for the depression as 
consequence model of diabetes. Additionally, the present study has the advantage of 
using objective biological markers in the measurement of the microvascular 
complications, including nerve conduction studies for neuropathy and albumin excretion 
rates for nephropathy, thus providing  more concrete and accurate measurements of the 
symptom severity without relying on potentially inaccurate subjective self-reports or 
global clinical judgments.   
Additionally, a multiple mediator model with bootstrapping was used to 
investigate the role of microvascular complications in the relationship between glycemic 
control and depressive symptomatology. This is a superior method of analysis than single 
51 
mediator models because it provides information of the total mediation effect of the 
microvascular complications, accounting for their intercorrelation, as well as specific 
indirect effects of each individual complication while controlling for the others. The 
analyses also statistically controlled for factors that are known to be associated with 
microvascular complications and depressive symptomatology. By controlling for baseline 
levels of variables included in the model as well as possible demographic confounds, the 
effects of A1c on depression and the meditational role of complications in this 
relationship could be identified independent of the known potential confounds. 
Clinical Implications 
The role of A1c and microvascular complications in the development of 
depressive symptomatology is an important factor to consider for clinical interventions. 
Because the relationship between A1c, microvascular complications, and depression may 
not be evident until later in the diabetes disease process, prevention of later psychological 
issues related to the disease should be focused on through an emphasis on effective 
disease management early on in the disease process. Diabetes self-management programs 
are considered a critical element of care for people with diabetes, as they have been found 
to be effective in improving glycemic control (Ellis, et al., 2004; Funnell, et al., 2009; 
Norris, Lau, Smith, Schmid, & Engelgau, 2002). Addressing related psychosocial issues 
is recommended as core components of self-management curriculum in addition to 
diabetes-specific behavioral and medical considerations (Funnell, et al., 2009). In light of 
the current findings it is recommended that diabetes self-management interventionists be 
especially vigilant about the psychological effects, particularly depression, of medical 
complications associated with diabetes. Consideration of these associations should be 
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given not only for the psychological health of people with diabetes, but also because the 
relationship between diabetes and depression may very well be bidirectional, and 
depression is likely to interfere with adherence to diabetes self-management regimens 
(Gonzalez, et al., 2008).  
Limitations 
 Some caveats should be noted. First, the current study was based on a long-term 
clinical research trial with a well-educated largely white sample of people with type 1 
diabetes. It is possible that clinical trials, which generally require participants follow 
fairly strict protocol regulations, attract a unique group of participants with characteristics 
that differ in significant ways from the general population. Furthermore, the homogeneity 
of race and educational levels in the current sample limits the applicability of the findings 
to the larger population. It is also possible that the relationships gleaned in the current 
study of people with type 1 diabetes may manifest somewhat differently in people with 
type 2 diabetes. Given that the overwhelming majority of cases of diabetes are type 2, it 
would be useful to test the applicability of the current models in a type 2 diabetes 
population. Furthermore, differences in sample size between the primary and secondary 
intervention cohorts may contribute to differences in power and, therefore, the ability to 
detect significant relationships between the variables in the mediation models. Further 
testing of these models in comparably sized samples of people with diabetes with varying 
stages of the disease and varying severities of complications should be tested. 
Additionally, despite using longitudinal experimental data, testing for mechanisms of the 
proposed relationship between A1c and depressive symptoms, and controlling for known 
variables that can influence the variables investigated, the possibility of a third 
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unmeasured variable accounting for the present relationships remains. Potential 
confounding variables such as self-management and adherence among others should be 
considered in future investigations.  
Future Directions 
 Continued exploration of the applicability of the current findings in a more 
heterogeneous sample including greater variability in educational attainment levels and 
racial and ethnic backgrounds in a longitudinal fashion would be prudent. Additionally, 
the models of the interrelationships between the A1c, microvascular complications, and 
depressive symptoms should be investigated in people with type 2 diabetes. Furthermore, 
future studies should investigate the mechanisms through which microvascular 
complications contribute to depressive symptomatology levels, such as by contributing to 
loss of reinforcement through pain and functional limitation.  
Conclusion 
 In summary, A1c mediated the relationship between DCCT group assignment and 
the severity of the diabetes related microvascular complications of retinopathy, 
nephropathy, and neuropathy. Furthermore, A1c was related to depressive symptom 
levels in the full sample and the secondary cohort, and this relationship was explained, in 
part, by the severity of microvascular complications. Longitudinal analyses provide 
evidence for the temporal relationship between these variables.  These results are 
consistent with the depression-as-consequence-model of depression, which proposes that 
depression occurs as a result of medical symptoms and complications that occur from 
poor diabetes self-management and poorly controlled glycemic levels. However, these 
54 
relationships may not be evident until later in the disease process when complications 
become increasingly severe and problematic.  
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Appendix A: 
Symptom Checklist-90-Revised Depression Dimension Subscale  
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Symptom Checklist-90-Revised Depression Dimension Subscale  
Instructions: Below is a list of problems people sometimes have. Please read each one 
carefully, and blacken the circle that best describes HOW MUCH THAT PROBLEM 
HAS DISTRESSED OR BOTHERED YOU DURING THE PAST 7 DAYS 
INCLUDING TODAY. Blacken the circle for only one number for each problem and do 
not skip any items. If you change your mind erase your first mark carefully.  
“Number” refers to the following descriptor phrases: 
0 = Not at all; 1 = A Little bit; 2 = Moderately; 3 = Quite a Bit; 4 = Extremely  
Item 0 1 2 3 4 
5. Loss of sexual interest or pleasure ○ ○ ○ ○ ○ 
14. Feeling low in energy or slowed down ○ ○ ○ ○ ○ 
15. Thoughts of ending your life ○ ○ ○ ○ ○ 
20. Crying easily ○ ○ ○ ○ ○ 
22. Feelings of being trapped or caught ○ ○ ○ ○ ○ 
26. Blaming yourself for things ○ ○ ○ ○ ○ 
29. Feeling lonely ○ ○ ○ ○ ○ 
30. Feeling blue ○ ○ ○ ○ ○ 
31. Worrying too much about things ○ ○ ○ ○ ○ 
32. Feeling no interest in things ○ ○ ○ ○ ○ 
54. Feeling hopeless about the future ○ ○ ○ ○ ○ 
71. Feeling everything is an effort ○ ○ ○ ○ ○ 
79. Feelings of worthlessness  ○ ○ ○ ○ ○ 
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Appendix B: 
Neuropathy Measurement Definition 
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Neuropathy Measurement Definition 
Nerve conduction of the dominant median (motor and sensory), peroneal (motor), 
and sural nerves was evaluated using standard techniques and stimulation-to-recording 
electrode distances or specified anatomical landmarks. A standardized physical and 
neurologic history was completed by DCCT neurologists at baseline, 5 years, and at 
study end. Peripheral, somatic, and autonomic neuropathic symptoms were investigated 
during the neurological examination. Deep-tendon reflexes and peripheral sensation 
including light touch, pin-prick, temperature, and position, were measured during the 
physical exam. Clinical neuropathy was indicated by abnormal findings in any two 
categories of neuropathic symptoms, sensory deficits, or impaired reflexes. Confirmed 
clinical neuropathy was defined as clinical neuropathy determined by a definite abnormal 
neurologic examination (defined by at least two of the following: sensory signs, absent or 
hypoactive reflexes consistent with distal symmetrical polyneuropathy, or positive 
responses among symptoms) confirmed by abnormal testing in either nerve conduction or 
autonomic nervous system testing or both (defined by a value above or below the 
absolute threshold of normal for amplitude, velocity of conduction, distal latency, or F-
wave latency in at least two anatomically distinct nerves). Possible clinical neuropathy 
was defined as a participant with only one abnormal finding among symptoms sensory 
signs, or absent or hypoactive reflexes, regardless of the normality of nerve conduction 
study outcomes. Secondary outcome variables assessed included clinical neuropathy 
(defined as a peripheral diabetic neuropathy diagnosis based on the presence of at least 
two of the following: physical symptoms, abnormalities on sensory examination, and 
decreased or absent deep-tendon reflexes), subclinical neuropathy (as defined by either 
abnormal nerve conduction, abnormal autonomic nervous system response, or 
abnormalities in both of these measurements without a definite diagnosis of peripheral 
neuropathy by clinical examination), abnormal nerve conduction, and abnormal 
autonomic nervous system test results (DCCT Research Group, 1995a).   
 
